Hims & Hersの第1四半期決算は明暗分かれる結果に

2026年05月11日(月)

AIによるレポート

Hims & Hers Healthが発表した第1四半期決算は、利益率の圧迫が響き、売上高が予想を下回った。

同社は、配合GLP-1医薬品から、Novo NordiskやEli Lillyとのブランド提携へと戦略を転換している。この方針転換は短期的には利益率に影響を与える見通しだが、配合薬に関連する法的リスクを低減させる狙いがある。

Hermès Q1 sales rise despite Middle East conflict impact

Hermès reported a 6% revenue increase in the first quarter of 2026, driven entirely by higher prices amid flat volume growth. The Middle East conflict led to a 6% sales drop in that region and a double-digit decline in its US-traded shares. Analysts view the sell-off as overdone, presenting a buying opportunity for long-term investors.

HLS Therapeutics releases Q4 2025 earnings call presentation

2026年03月12日(木) AIによるレポート

HLS Therapeutics Inc. (TSX: HLS:CA) has published a slide deck for its 2025 fourth-quarter earnings call, released on March 13, 2026, following an earnings summary dated March 12, 2026.

ビジネス

Premium Brands Holdings releases 2026 first quarter earnings presentation

技術

HCL Tech shares plunge over 9% after weak Q4 results

ビジネス

Greenlight Capital funds return 6.5% in Q1 2026

Palantir reports strong Q1 earnings beat

Palantir Technologies Inc. delivered exceptional first-quarter results, with revenue exceeding consensus estimates by 6% and earnings per share nearly 20% above forecasts. The company's revenue grew over 80% year-over-year, outpacing most tech peers. Despite the strong performance, shares did not rally amid valuation concerns.

LVMH reports 1% sales growth in Q1 despite fashion decline

2026年04月13日(月) AIによるレポート

LVMH announced first-quarter sales rose 1% organically to €19.12 billion. Fashion and leather goods sales fell 2% to €9.25 billion, better than the prior quarter but below expectations. The Middle East conflict impacted growth by about 1 percentage point.

ビジネス